NYSE:ZBH

Zimmer Biomet Competitors

$172.88
+0.35 (+0.20 %)
(As of 04/20/2021 12:12 PM ET)
Add
Compare
Today's Range
$172.31
Now: $172.88
$175.13
50-Day Range
$156.14
MA: $162.31
$171.88
52-Week Range
$108.78
Now: $172.88
$173.22
Volume16,595 shs
Average Volume1.23 million shs
Market Capitalization$36.01 billion
P/E Ratio1,080.57
Dividend Yield0.56%
Beta1.34

Competitors

Zimmer Biomet (NYSE:ZBH) Vs. ISRG, EW, ALGN, STE, SNN, and MSA

Should you be buying ZBH stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Zimmer Biomet, including Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Align Technology (ALGN), STERIS (STE), Smith & Nephew (SNN), and MSA Safety (MSA).

Zimmer Biomet (NYSE:ZBH) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

87.2% of Zimmer Biomet shares are held by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are held by institutional investors. 0.4% of Zimmer Biomet shares are held by insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Zimmer Biomet and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zimmer Biomet$7.98 billion4.51$1.13 billion$7.8721.97
Intuitive Surgical$4.48 billion21.47$1.38 billion$9.9581.65

Intuitive Surgical has lower revenue, but higher earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Zimmer Biomet has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Zimmer Biomet and Intuitive Surgical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zimmer Biomet131632.91
Intuitive Surgical181102.50

Zimmer Biomet currently has a consensus target price of $167.8636, suggesting a potential downside of 3.41%. Intuitive Surgical has a consensus target price of $750.9444, suggesting a potential downside of 7.85%. Given Zimmer Biomet's stronger consensus rating and higher probable upside, research analysts clearly believe Zimmer Biomet is more favorable than Intuitive Surgical.

Profitability

This table compares Zimmer Biomet and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zimmer Biomet0.52%10.07%4.93%
Intuitive Surgical24.45%12.08%10.44%

Summary

Zimmer Biomet beats Intuitive Surgical on 8 of the 15 factors compared between the two stocks.

Zimmer Biomet (NYSE:ZBH) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Zimmer Biomet and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zimmer Biomet0.52%10.07%4.93%
Edwards Lifesciences18.18%29.00%18.10%

Analyst Ratings

This is a summary of recent recommendations for Zimmer Biomet and Edwards Lifesciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zimmer Biomet131632.91
Edwards Lifesciences261302.52

Zimmer Biomet presently has a consensus price target of $167.8636, suggesting a potential downside of 3.41%. Edwards Lifesciences has a consensus price target of $91.1569, suggesting a potential upside of 0.43%. Given Edwards Lifesciences' higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Zimmer Biomet.

Valuation & Earnings

This table compares Zimmer Biomet and Edwards Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zimmer Biomet$7.98 billion4.51$1.13 billion$7.8721.97
Edwards Lifesciences$4.35 billion12.95$1.05 billion$1.8648.68

Zimmer Biomet has higher revenue and earnings than Edwards Lifesciences. Zimmer Biomet is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

87.2% of Zimmer Biomet shares are held by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are held by institutional investors. 0.4% of Zimmer Biomet shares are held by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Zimmer Biomet has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Summary

Zimmer Biomet beats Edwards Lifesciences on 9 of the 15 factors compared between the two stocks.

Align Technology (NASDAQ:ALGN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Align Technology and Zimmer Biomet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Align Technology76.00%68.99%46.64%
Zimmer Biomet0.52%10.07%4.93%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Align Technology and Zimmer Biomet, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Align Technology13902.62
Zimmer Biomet131632.91

Align Technology presently has a consensus price target of $502.1667, suggesting a potential downside of 14.97%. Zimmer Biomet has a consensus price target of $167.8636, suggesting a potential downside of 3.41%. Given Zimmer Biomet's stronger consensus rating and higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than Align Technology.

Valuation and Earnings

This table compares Align Technology and Zimmer Biomet's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$2.41 billion19.52$442.78 million$4.96119.68
Zimmer Biomet$7.98 billion4.51$1.13 billion$7.8721.97

Zimmer Biomet has higher revenue and earnings than Align Technology. Zimmer Biomet is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

85.8% of Align Technology shares are held by institutional investors. Comparatively, 87.2% of Zimmer Biomet shares are held by institutional investors. 1.2% of Align Technology shares are held by insiders. Comparatively, 0.4% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Align Technology has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.

Summary

Zimmer Biomet beats Align Technology on 9 of the 15 factors compared between the two stocks.

STERIS (NYSE:STE) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for STERIS and Zimmer Biomet, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
STERIS02302.60
Zimmer Biomet131632.91

STERIS presently has a consensus price target of $214.25, suggesting a potential upside of 1.74%. Zimmer Biomet has a consensus price target of $167.8636, suggesting a potential downside of 3.41%. Given STERIS's higher probable upside, equities research analysts clearly believe STERIS is more favorable than Zimmer Biomet.

Dividends

STERIS pays an annual dividend of $1.60 per share and has a dividend yield of 0.8%. Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.6%. STERIS pays out 28.4% of its earnings in the form of a dividend. Zimmer Biomet pays out 12.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has increased its dividend for 15 consecutive years and Zimmer Biomet has increased its dividend for 1 consecutive years. STERIS is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

90.0% of STERIS shares are held by institutional investors. Comparatively, 87.2% of Zimmer Biomet shares are held by institutional investors. 1.2% of STERIS shares are held by insiders. Comparatively, 0.4% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

STERIS has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Profitability

This table compares STERIS and Zimmer Biomet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
STERIS13.97%14.44%9.32%
Zimmer Biomet0.52%10.07%4.93%

Earnings and Valuation

This table compares STERIS and Zimmer Biomet's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$3.03 billion5.86$407.61 million$5.6436.89
Zimmer Biomet$7.98 billion4.51$1.13 billion$7.8721.97

Zimmer Biomet has higher revenue and earnings than STERIS. Zimmer Biomet is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Zimmer Biomet (NYSE:ZBH) and Smith & Nephew (NYSE:SNN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Zimmer Biomet and Smith & Nephew, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zimmer Biomet131632.91
Smith & Nephew24602.33

Zimmer Biomet presently has a consensus target price of $167.8636, suggesting a potential downside of 3.41%. Smith & Nephew has a consensus target price of $47.1667, suggesting a potential upside of 19.26%. Given Smith & Nephew's higher probable upside, analysts clearly believe Smith & Nephew is more favorable than Zimmer Biomet.

Dividends

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.6%. Smith & Nephew pays an annual dividend of $0.90 per share and has a dividend yield of 2.3%. Zimmer Biomet pays out 12.2% of its earnings in the form of a dividend. Smith & Nephew pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zimmer Biomet has increased its dividend for 1 consecutive years and Smith & Nephew has increased its dividend for 1 consecutive years.

Institutional & Insider Ownership

87.2% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 8.9% of Smith & Nephew shares are owned by institutional investors. 0.4% of Zimmer Biomet shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Zimmer Biomet has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Zimmer Biomet and Smith & Nephew's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zimmer Biomet0.52%10.07%4.93%
Smith & NephewN/AN/AN/A

Valuation and Earnings

This table compares Zimmer Biomet and Smith & Nephew's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zimmer Biomet$7.98 billion4.51$1.13 billion$7.8721.97
Smith & Nephew$5.14 billion3.38$600 million$2.0419.37

Zimmer Biomet has higher revenue and earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Summary

Zimmer Biomet beats Smith & Nephew on 14 of the 17 factors compared between the two stocks.

Zimmer Biomet (NYSE:ZBH) and MSA Safety (NYSE:MSA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Zimmer Biomet and MSA Safety, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zimmer Biomet131632.91
MSA Safety01202.67

Zimmer Biomet presently has a consensus target price of $167.8636, suggesting a potential downside of 3.41%. MSA Safety has a consensus target price of $151.50, suggesting a potential downside of 1.39%. Given MSA Safety's higher probable upside, analysts clearly believe MSA Safety is more favorable than Zimmer Biomet.

Dividends

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.6%. MSA Safety pays an annual dividend of $1.72 per share and has a dividend yield of 1.1%. Zimmer Biomet pays out 12.2% of its earnings in the form of a dividend. MSA Safety pays out 35.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zimmer Biomet has increased its dividend for 1 consecutive years and MSA Safety has increased its dividend for 11 consecutive years. MSA Safety is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

87.2% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 77.2% of MSA Safety shares are owned by institutional investors. 0.4% of Zimmer Biomet shares are owned by insiders. Comparatively, 7.0% of MSA Safety shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Zimmer Biomet has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, MSA Safety has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

Profitability

This table compares Zimmer Biomet and MSA Safety's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zimmer Biomet0.52%10.07%4.93%
MSA Safety10.40%23.96%10.13%

Valuation and Earnings

This table compares Zimmer Biomet and MSA Safety's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zimmer Biomet$7.98 billion4.51$1.13 billion$7.8721.97
MSA Safety$1.40 billion4.30$136.44 million$4.8032.10

Zimmer Biomet has higher revenue and earnings than MSA Safety. Zimmer Biomet is trading at a lower price-to-earnings ratio than MSA Safety, indicating that it is currently the more affordable of the two stocks.

Summary

Zimmer Biomet beats MSA Safety on 11 of the 18 factors compared between the two stocks.


Zimmer Biomet Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$812.39+0.1%$96.03 billion$4.48 billion92.53News Coverage
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.4$90.55+2.2%$55.09 billion$4.35 billion72.44
Align Technology logo
ALGN
Align Technology
1.9$593.61+1.7%$47.78 billion$2.41 billion27.01Analyst Revision
STERIS logo
STE
STERIS
2.1$208.05+0.3%$17.81 billion$3.03 billion42.20Increase in Short Interest
Smith & Nephew logo
SNN
Smith & Nephew
2.1$39.52+0.2%$17.34 billion$5.14 billion19.37Analyst Revision
News Coverage
MSA Safety logo
MSA
MSA Safety
2.1$154.10+0.4%$6.05 billion$1.40 billion43.65News Coverage
Avanos Medical logo
AVNS
Avanos Medical
1.5$45.00+0.8%$2.14 billion$697.60 million155.17
Eargo logo
EAR
Eargo
1.0$46.64+1.4%$1.81 billionN/A0.00Insider Selling
Increase in Short Interest
News Coverage
Establishment Labs logo
ESTA
Establishment Labs
1.2$65.77+1.9%$1.59 billion$89.57 million-38.92News Coverage
Gap Down
Inogen logo
INGN
Inogen
1.2$61.60+2.0%$1.40 billion$361.94 million-684.37Insider Selling
News Coverage
Sientra logo
SIEN
Sientra
1.6$6.65+3.0%$392.32 million$83.70 million-3.74Increase in Short Interest
News Coverage
Invacare logo
IVC
Invacare
1.6$8.58+1.5%$290.88 million$927.96 million-6.98
Lakeland Industries logo
LAKE
Lakeland Industries
1.8$28.00+0.0%$224.48 million$107.81 million7.95Earnings Announcement
Analyst Upgrade
SMTI
Sanara MedTech
0.8$28.05+0.5%$212.59 million$11.77 million-21.74Decrease in Short Interest
News Coverage
Surgalign logo
SRGA
Surgalign
1.7$1.77+2.8%$200.69 million$308.38 million-0.98Increase in Short Interest
Surgalign logo
SRGA
Surgalign
1.4$1.77+2.8%$200.69 million$308.38 million-0.98Increase in Short Interest
Conformis logo
CFMS
Conformis
1.3$0.81+5.0%$155.43 million$77.43 million-2.39News Coverage
Gap Up
CollPlant Biotechnologies logo
CLGN
CollPlant Biotechnologies
1.1$13.99+3.6%$82.16 million$2.32 million-7.00
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.4$1.73+2.9%$82.07 million$4.87 million-1.37
Predictive Oncology logo
POAI
Predictive Oncology
1.3$0.98+7.5%$51.23 million$1.41 million-0.16News Coverage
Gap Up
AHPI
Allied Healthcare Products
0.5$4.20+5.5%$17.76 million$31.89 million0.00
NanoVibronix logo
NAOV
NanoVibronix
0.5$0.85+0.1%$11.39 million$530,000.00-1.42
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.